To amend sections 339.78, 339.81, 1751.91, 3923.89, 4729.01, and 4729.39 and to enact sections 4729.21 and 4729.211 of the Revised Code to authorize pharmacists to treat minor health conditions and to name this act the Pharmacist Prescribing Authority Act.
HB629, titled the Pharmacist Prescribing Authority Act, expands the scope of pharmacy practice in Ohio by authorizing pharmacists to treat a defined set of minor or generally self-limiting health conditions for patients age 13 and older. Under a protocol established by certain physicians, advanced practice registered nurses, or physician assistants, pharmacists could order or perform limited tests and screenings, interpret results, and prescribe non-controlled drugs and drug therapy-related devices for conditions such as influenza, strep pharyngitis, COVID-19, bronchitis, sinusitis, lice, ringworm, athlete’s foot, urinary tract infections, and HIV prevention services including PrEP and PEP. The bill also allows pharmacists to prescribe and administer tuberculin skin test products for tuberculosis screening, subject to training and referral requirements.
The bill further revises Ohio’s pharmacy and insurance statutes to recognize these new pharmacist services. It amends the definition of the “practice of pharmacy” to include pharmacist prescribing authority and tuberculin testing, and it updates the definition of “licensed health professional authorized to prescribe drugs” to include pharmacists acting under the new sections. It also requires health insuring corporations, sickness and accident insurers, and public employee benefit plans to reimburse pharmacists for services covered under the new pharmacist-prescribing provisions when the underlying policy would cover the service if provided by another prescriber. In addition, it makes conforming changes to tuberculosis reporting and confidentiality provisions so that pharmacists are treated as health care providers for those purposes.
The bill’s impact on state law would be significant for pharmacy practice, public health reporting, and insurance reimbursement. It would create a new statutory framework for pharmacist-led treatment protocols, require the State Board of Pharmacy to adopt implementing rules in consultation with the medical and nursing boards, and establish documentation, referral, and signage requirements for participating pharmacies. It would also expand the list of professionals who may report tuberculosis and protect those reports as confidential public health information. The bill applies its insurance reimbursement changes prospectively to contracts and policies delivered, issued, modified, or renewed on or after the effective date.
Because the bill was only introduced and had no recorded committee testimony or votes in the provided materials, there is no formal legislative record of support or opposition in the context supplied. The text itself suggests a policy goal of improving access to care and reducing burden on physicians by allowing pharmacists to handle routine conditions and screening services. The overall tone of the proposal is expansionary and permissive, with detailed guardrails intended to keep pharmacist prescribing limited to protocols, age thresholds, training requirements, and follow-up referrals.
The main points of potential contention are likely to center on scope of practice, patient safety, and oversight. Supporters would likely emphasize convenience, access, and reimbursement parity for pharmacist-delivered care, while opponents or skeptics may question whether pharmacists should diagnose or prescribe for conditions that can resemble more serious illnesses, especially given the bill’s inclusion of COVID-19, HIV prevention, and tuberculosis screening. The requirement that protocols be established by nearby physicians or advanced practice clinicians, and the exclusion of controlled substances, appear designed to address those concerns by limiting independent pharmacist discretion.
HB629 would amend Ohio’s pharmacy, insurance, and tuberculosis reporting laws to authorize pharmacists to provide limited treatment and screening services, prescribe certain non-controlled drugs and devices under protocol, and be reimbursed for those services when covered by insurance. It would also expand the statutory definition of pharmacy practice and make pharmacists part of the public health reporting framework for tuberculosis, while requiring the State Board of Pharmacy and other boards to adopt implementing rules.
The bill appears to be framed positively as an access-to-care and professional-expansion measure, with no recorded committee testimony or votes in the provided materials to show formal opposition or support. Based on the text, the proposal is cautious rather than sweeping, using protocols, training, age limits, and referral requirements to balance expanded pharmacist authority with patient-safety concerns.
Likely points of contention include whether pharmacists should be allowed to assess symptoms, order tests, and prescribe for conditions that may overlap with more serious illnesses; whether the protocol-based model provides enough physician oversight; and whether insurers should be required to reimburse pharmacist services on par with other prescribers. Supporters would likely focus on access, convenience, and workforce efficiency, while critics may worry about scope of practice, diagnostic accuracy, and continuity of care.